Skip to main content

Saniona Announces Poster Presentation at the European Congress of Endocrinology Virtual Annual Meeting

Written by Customer Service on . Posted in Public Companies.

PRESS RELEASE24 August 2020Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that a poster highlighting results from a phase 2 clinical trial of Tesomet for hypothalamic obesity will be presented at the 22nd European Congress of Endocrinology virtual annual meeting being held 5-9 September 2020. Professor Ulla Feldt-Rasmussen, M.D. DMSc (Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital) will present the poster titled “A Randomized-Controlled Trial of Tesomet Resulted in Significant Weight Loss in Hypopituitary Patients with Hypothalamic Obesity”.For more information, please contactRudolf Baumgartner, CMO & Head of Clinical Development, Saniona, Email: rudolf.baumgartner@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on August 24, 2020.About SanionaSaniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.About TesometTesomet is a fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Tesofensine and Tesomet have demonstrated strong weight reduction in overweight patient populations driven primarily through increased metabolic output and appetite suppression. Saniona is advancing Tesomet for hypothalamic obesity and Prader Willi syndrome, two severe rare eating disorders characterized by obesity and loss of appetite control. The clinical programs are currently in mid/late stage development.
Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.About hypothalamic obesitySaniona is evaluating Tesomet for the treatment of hypothalamic obesity (HO), a rare disorder characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic disorders. The company reported positive data from a Phase 2 clinical trial in HO in April 2020 and is currently conducting an open-label extension of this study, with data expected in Q4 2020. Saniona intends to pursue a meeting with the FDA in Q4 2020 to help define a regulatory path forward for Tesomet in HO.Attachment20200824 – PR – eECO Poster – UK

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.